WallStSmart
TNYA

Tenaya Therapeutics Inc

NASDAQ: TNYA · HEALTHCARE · BIOTECHNOLOGY

$1.00
-5.70% today

Updated 2026-06-05

Market cap
$171.43M
P/E ratio
P/S ratio
761.91x
EPS (TTM)
$-0.44
Dividend yield
52W range
$1 – $2
Volume
4.0M

Tenaya Therapeutics Inc (TNYA) Financial statements

SEC filings — annual and quarterly data.

Balance sheet — annual

Item2019202020212022202320242025
Total assets$38.00M$148.16M$316.65M$278.94M$170.51M$119.94M$146.92M
Cash & equivalents$23.87M$128.53M$38.13M$95.27M$45.68M$4.32M$100.55M
Current assets$27.74M$129.96M$255.36M$193.75M$111.58M$67.38M$105.59M
Total liabilities$81.74M$8.72M$38.12M$35.57M$31.09M$27.09M$23.66M
Current liabilities$4.12M$5.04M$21.77M$24.25M$22.73M$15.97M$15.44M
Long-term debt
Shareholder equity$-43.74M$139.44M$278.53M$243.38M$139.42M$92.85M$123.27M
Retained earnings$-44.42M$-82.81M$-155.53M$-279.20M$-403.28M$-514.41M$-605.01M
Accounts receivable$2.25M
Inventory$-19.95M
Goodwill

Frequently asked questions

What is Tenaya Therapeutics Inc's revenue?

Tenaya Therapeutics Inc's trailing twelve-month revenue is $225000.00. Revenue is the top line the whole model builds on, and at this scale the question shifts from how fast it grows to whether margins hold as it compounds.

How much free cash flow does TNYA generate?

TNYA produced $-68.88M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is TNYA's balance sheet healthy?

TNYA holds $100.55M in cash and equivalents against — in long-term debt, on $123.27M of shareholder equity. That debt is best read against the cash flow the business throws off each year.